STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling

Genes and Immunity

Volumn 11, Issue 5, 2010, Pages 432-438

  Gestermann, N ^a,f   Mekinian, A ^a,f   Comets, E ^a,f   Loiseau, P ^b,f   Puechal, X ^c,f   Hachulla, E ^d,f   Gottenberg, J E ^e,f   Mariette, X ^a,f   Miceli Richard, C ^a,f  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER DU MANS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f BICÊTRE HOSPITAL   (France)

Author keywords

genetic polymorphism; promoter; Sj gren's syndrome; STAT4

Indexed keywords

GAMMA INTERFERON; IFITM1 PROTEIN; INTERFERON; MESSENGER RNA; MX1 PROTEIN; PROTEIN; PROTEIN KINASE R; STAT1 PROTEIN; STAT4 PROTEIN; STAT4ALPHA PROTEIN; STAT4BETA PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; GUANINE NUCLEOTIDE BINDING PROTEIN; LEU-13 ANTIGEN; MEMBRANE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN; STAT4 PROTEIN, HUMAN;

ARTICLE; CAUCASIAN; CELL LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE FREQUENCY; GENE FUNCTION; GENE INDUCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; RISK;

ANTIGENS, DIFFERENTIATION; CASE-CONTROL STUDIES; COHORT STUDIES; EIF-2 KINASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GTP-BINDING PROTEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; MYXOVIRUS RESISTANCE PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; STAT4 TRANSCRIPTION FACTOR;

EID: 77954886593     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2010.29     Document Type: Article

References (22)

1. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009; 10: 285-296.
2. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T et al. Activation of IFN pathways and plasmacy-toid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770-2775.
3. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534-1544.
4. Miceli-Richard C, Gestermann N, Ittah M, Comets E, Loiseau P, Puechal X et al. The CGGGG insertion/deletion polymorph¬ism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 2009; 60: 1991-1997.
5. Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nord-mark G, Sandling JK et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008; 17: 872-881.
6. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, Wang C et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun 2009; 10: 68-76.
7. Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP et al. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun 2008; 9: 267-270.
8. Abelson AK, Delgado-Vega AM, Kozyrev SV, Sanchez E, Velazquez-Cruz R, Eriksson N et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68: 1746-1753.
9. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182: 34-38.
10. Orozco G, Alizadeh BZ, Delgado-Vega AM, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D et al. Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum 2008; 58: 1974-1980.
11. Martinez A, Varade J, Marquez A, Cenit MC, Espino L, Perdigones N et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 2008; 58: 2598-2602.
12. Zervou MI, Sidiropoulos P, Petraki E, Vazgiourakis V, Krasoudaki E, Raptopoulou A et al. Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous popula¬tion. Hum Immunol 2008; 69: 567-571.
13. Namjou B, Sestak AL, Armstrong DL, Zidovetzki R, Kelly JA, Jacob N et al. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythe-matosus in different racial groups. Arthritis Rheum 2009; 60: 1085-1095.
14. Dieude P, Guedj M, Wipff J, Ruiz B, Hachulla E, Diot E et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60: 2472-2479.
15. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-986.
16. Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008; 17: 2868-2876.
17. Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60: 2468-2471.
18. Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S. STAT4 gene polymorphism is asso¬ciated with psoriasis in the genetically homogeneous popula¬tion of Crete, Greece. Hum Immunol 2009; 70: 738-741.
19. Hoey T, Zhang S, Schmidt N, Yu Q, Ramchandani S, Xu X et al. Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses. EMBO J 2003; 22: 4237-4248.
20. Farrar JD, Smith JD, Murphy TL, Murphy KM. Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J Biol Chem 2000; 275: 2693-2697.
21. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infec¬tion. Science 2002; 297: 2063-2066.
22. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann rheum dis 2002; 61: 554-558.